Trial · NCT03464136
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With Clinical Remission at Week 52 | Week 52 | Full analysis set (FAS) which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Corticosteroid-free Remission at Week 52 | Week 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Response at Week 52 | Week 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants in Patient Reported Outcome (PRO)-2 Symptom Remission at Week 52 | Week 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Remission at Week 16 | Week 16 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Endoscopic Remission at Week 52 | Week 52 | FAS among participants with SES-CD Score \>=3 at Baseline. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Remission Through Week 52 | Weeks 2, 8, 16, 24, 32, 40, 48, and 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical Response Through Week 52 | Weeks 2, 8, 16, 24, 32, 40, 48, and 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Durable Clinical Response at Week 52 | Week 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Durable Clinical Remission at Week 52 | Week 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Abdominal Pain (AP) Improvement Through Week 52 | Weeks 2, 8, 16, 24, 32, 40, 48, and 52 | FAS among participants with mean daily AP Score \>0 at Baseline. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Reduction in Frequency of Diarrhea Through Week 52 | Weeks 2, 8, 16, 24, 32, 40, 48, and 52 | FAS among participants with mean daily stool frequency \>1 at Baseline. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Clinical and Biomarker Remission at Weeks 8, 16 and 52 | At Weeks 8, 16 and 52 | FAS which was defined as all randomized participants. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Adverse Events (AEs) | Up to Week 52 and up to Week 76 | Safety analysis set included all the participants who were randomized and received at least one administration of study agent in the study. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Infections | Up to Week 52 and up to Week 76 | Safety analysis set included all the participants who were randomized and received at least one administration of study agent in the study. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Serious Infections | Up to Week 52 and up to Week 76 | Safety analysis set included all the participants who were randomized and received at least one administration of study agent in the study. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Serious Adverse Events (SAEs) | Up to Week 52 and up to Week 76 | Safety analysis set included all the participants who were randomized and received at least one administration of study agent in the study. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Anti-drug Antibodies | Up to Week 52 | Immunogenicity analysis set included all participants who had received at least 1 administration of study agent and have at least one valid blood sample drawn for detection of antibodies to study agent. | percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03464136/outcomes